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Objectives: A co-morbid diagnosis of cancer and dementia (cancer-dementia) may have unique 
implications for patient cancer-related experience. The objectives were to estimate prevalence of 
cancer-dementia and related experiences of people with dementia, their carers and cancer clinicians 
including cancer screening, diagnosis, treatment and palliative care. Method: Databases were 
searched (CINAHL, Psychinfo, Medline, Embase, BNI) using key terms such as dementia, cancer and 
experience. Inclusion criteria were: a) English language, b) published any time until early 2016, c) 
diagnosis of cancer-dementia and d) original articles that assessed prevalence and/or cancer-related 
experiences including screening, cancer treatment and survival. Due to variations in study design and 
outcomes, study data were synthesized narratively. Results: Forty-seven studies were included in the 
review with a mix of quantitative (n = 44) and qualitative (n = 3) methodologies. Thirty-four studies 
reported varied cancer-dementia prevalence rates (range 0.2-45.6%); the others reported reduced 
likelihood of receiving: cancer screening, cancer staging information, cancer treatment with curative 
intent and pain management, compared to those with cancer only. The findings indicate poorer 
cancer-related clinical outcomes including late diagnosis and higher mortality rates in those with 
cancer-dementia despite greater health service use. Conclusions: There is a dearth of good quality 
evidence investigating the cancer-dementia prevalence and its implications for successful cancer 
treatment. Findings suggest that dementia is associated with poorer cancer outcomes although the 
reasons for this are not yet clear.  Further research is needed to better understand the impact of cancer-
dementia and enable patients, carers and clinicians to make informed cancer-related decisions.  
Keywords: Dementia and Cognitive Disorders, Cancer, Physical Health Status, Health 
Service Use, Systematic Review  
Word count: 3848 
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An increase in the ageing population coupled with improved life expectancy, raises unique 
challenges for health and social care. It is estimated that by 2050, at least 30% of the global 
population will be aged 65 years or older resulting in the increased likelihood and 
management of chronic and multiple illnesses, otherwise known as multi-morbidity (Barnett 
et al., 2012; World Health Organization, 2015). By 2040, it is predicted that nearly one 
quarter of people aged over 65 years in England and Wales will have a cancer diagnosis and 
older age is linked with poorer cancer outcomes including lower likelihood of successful 
completion of cancer treatment (Cancer Research UK, 2015; Maddams, Utley, & Møller, 
2012). An aging population is also linked to a projected increase in the world-wide 
prevalence of dementia as approximately 5-9% (Prince et al., 2015). Taken together, this 
means that the number of older people with co-morbid cancer and dementia is also likely to 
rise; although it is currently unclear what the co-morbid cancer-dementia prevalence is.  
A diagnosis of dementia has additional implications in accessing healthcare for cancer 
diagnosis and treatment, due to cognitive functioning and communication difficulties 
associated with the disease (Dooley, Bailey, & McCabe, 2015). Behaviour and psychological 
symptoms of dementia are also likely to also impact on undiagnosed acute illness and 
healthcare use (Hodgson, Gitlin, Winter & Czekanski, 2011; Silwanowicz et al, 2016). In the 
context of dementia, little is known about the experience of being diagnosed with cancer or 
the process of receiving cancer treatment, cancer-related decision-making and the impact of 
those decisions. The complexities of managing cancer in a person with dementia is likely to 
place a significant burden on patients, their family carers, and health care professionals 
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including cancer clinicians (HCP), particularly with greater involvement in cancer-related 
decisions placed to support the person with dementia (Alzheimer's Society, 2009; All-Party 
Parliamentary Group on Dementia, 2016; Guthrie Bruce, 2012).  
The aim of this review was to systematically identify and critically review studies that 
investigated the prevalence of co-morbid cancer and dementia and its effect on cancer-related 
pathways including prevention, detection and diagnosis, cancer treatments and clinical 
outcomes including palliative care. Cancer patients’, informal caregivers’, and HCPs’ 
experiences and views were included. Specific objectives were to: 
I. Estimate the prevalence of cancer-dementia  
II. Describe cancer related experiences of people with cancer-dementia , their informal 
caregivers and HCPs at any stage of the cancer pathway 
III. Describe cancer-related outcomes for people with cancer-dementia  
Methods  
Search strategy and selection criteria 
Given the likely range of mixed methods used to investigate cancer-dementia, this review 
was conducted using a structured narrative approach [13] and follows the PRISMA checklist 
for reporting systematic reviews (Moher, Liberati, Tetzlaff, & Altman, 2009; Pope, Mays, & 
Popay, 2007). This approach enables qualitative and quantitative studies to be reviewed 
Page 3 of 55
URL: http:/mc.manuscriptcentral.com/camh





























































For Peer Review Only
4 
 
simultaneously in order to synthesise the existing evidence and identify gaps when it is not 
practical to apply meta-analytic review methods. 
A systematic search of electronic databases (CINAHL, BNI, Embase, PsycINFO and 
MEDLINE) was conducted in December 2015 and updated June 2016. All study designs 
were considered for inclusion with no publication date limitations. Two authors (LM and JY) 
reviewed papers for inclusion criteria and discussed any disagreements. The search strategy 
was tailored to the review objectives using combinations of the following MesH search terms, 
which were adapted for terms used by each database:  
Comorbidity AND dementia OR alzheimer OR lewy AND tumour OR cancer OR neoplasms 
AND prevalence AND economic OR Cost OR expenditure. Dementia OR alzheimer adjacent 
by 5 words to cancer OR tumour OR neoplasm OR Oncol*, AND treatment outcome OR 
mortality OR experience OR burden OR distress OR attitude OR preference* adjacent by five 
words to patient OR carer OR clinician OR nurse OR doctor OR family OR relative 
AND/OR information adjacent by five words to needs AND/OR decision-making. 
The reference lists of included studies and relevant review papers were scanned for additional 
studies not already found in the searches. An additional search of the main authors of 
included studies was conducted. 
The following inclusion criteria were used: 
• Participants aged 18 years and older 
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• Investigated cancer-dementia using medical classification in methodology e.g. 
International Classification of Diseases (ICD), medical notes or Diagnostic and 
Statistical Manual for Mental Disorders (DSM-V) psychiatric interview 
• Full empirical research article written in the English language 
The following exclusion criteria were used 
• Comparisons between samples of patients with cancer and samples of patients with 
dementia (or other illness), but not those with cancer-dementia 
• Self-reported diagnoses (of cancer or dementia) not confirmed by a clinician 
• Reviews, opinions, editorials, conference abstracts, case studies 
Given the mixed methods of studies identified in the review, the Mixed Methods Appraisal 
Tool (MMAT; Pluye et al 2009, 2011) tool was used to appraise each study that met 
inclusion criteria. This has been specifically developed for mixed-method reviews to appraise 
qualitative and quantitative designs concurrently. Each study receives an overall quality 
percentage score based on four items that reflect study design, appropriateness of outcome 
measures including validity, randomisation (if appropriate) and completeness of data. The 
score ranges from 0 to 100%; – (0% of quality criteria met); * (25% of quality criteria met); ** (50% 
of quality criteria met); *** (75% of quality criteria met) or **** (100% of quality criteria met). 
Results  
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In total, 47 studies met inclusion criteria and one or more of the review objectives (see Figure 
1), 14 of which specifically investigated cancer-dementia as an aim of the paper. Most studies 
were conducted in the USA (n=31), Denmark (n=7), two studies each from the Netherlands, 
Sweden, and Japan, and one study from England, Taiwan and Switzerland (Table 1). Three 
studies received a quality appraisal rating of – (0%), 13 studies received a rating of *, 14 
received a rating of **, 17 studies met criteria for 3 of 4 items *** and one study met full 
criteria **** (100%). Studies are presented in the results using sub-headings related to each 
of the review objectives.  
[Table 1 insert here]  
[Figure 1 insert here]  
Objective 1 
1.1 Prevalence of cancer-dementia 
Thirty-four studies reported prevalence estimates using a range of settings predominantly 
nationwide, nursing homes and individual hospitals (see Table 2). All but three studies 
investigated the prevalence of dementia in samples of patients with cancer whilst one study 
reported cancer-related data in a nationwide sample of hospital in-patients with Alzheimer’s 
disease (Beydoun et al., 2015). The remaining two studies used a sample of end-of-life 
nursing home hospice residents including those with cancer-dementia (Miller, Gozalo, & 
Mor, 2001; Miller, Mor, Wu, Gozalo, & Lapane, 2002).  
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The lowest prevalence rates for dementia were reported in five Danish studies of ovarian 
(0.2%), breast (both 0.5%) and prostate (both 0.6%) cancer (Nguyen-Nielsen et al., 2013; 
Ording, Cronin-Fenton, et al., 2013; Ording, Garne, et al., 2013; Ording et al., 2016; Tetsche, 
Nørgaard, Jacobsen, Wogelius, & Sørensen, 2008). The highest cancer-dementia prevalence 
rates of 32% and 45.6% were reported in the two US studies with samples of nursing home 
hospice resident studies (Miller et al., 2001; Miller et al., 2002). Seven studies compared 
dementia prevalence rates between cancer patients and a non-cancer control group; four 
studies reported similar rates between the two groups (range: 0.5-1% in cancer-dementia and 
0.4-1.2% in non-cancer) (Erichsen, Horvath-Puho, Iversen, Lash, & Sorensen, 2013; 
Jorgensen, Hallas, Friis, & Herrstedt, 2012; Ording, Cronin-Fenton, et al., 2013; Ording, 
Garne, et al., 2013); two studies found higher rates of cancer-dementia patients in hospice 
nursing home residents (range 32-43.2% in cancer-dementia and 16-28.5% in non-cancer ) 
(Miller et al., 2001; Miller et al., 2002): and one study found slightly lower rates of dementia 
in patients with cancer (1.3% in cancer-dementia and 1.9% in non-cancer). 
[Table 2 insert here] 
Objective 2 
Included studies for objective two are presented as cancer screening, cancer diagnosis, cancer 
treatment decisions and HCP views. 
2.1 Cancer screening 
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Only three studies explored dementia and cancer screening (Smyth, 2009; Torke, Schwartz, 
Holtz, Montz, & Sachs, 2013; Walter et al., 2009). In a sample of male veterans with and 
without dementia, study findings show that only 19% of those with a diagnosis of dementia 
(2% of the sample) received colorectal cancer screening over 2 years compared to 47% with 
no morbidity or other morbidities such as diabetes (48%) or congestive heart failure (41%) 
(Walter et al., 2009). Exploring possible reasons for reduced likelihood of receiving breast 
cancer screening, two studies (Smyth, 2009; Torke et al., 2013) explored the impact a 
diagnosis of dementia had on decision-making. Findings indicated that the involvement of the 
person with dementia in the decision-making process, potential distress from screening test 
procedures and the influence of the clinician are important decision-making factors.  
2.2 Cancer diagnosis  
Ten studies reported the impact of having a dementia diagnosis on the diagnostic processes of 
cancer (see Table 3). Five studies reported that some patients with dementia were diagnosed 
with cancer at autopsy three of which included control groups for comparison (Burke et al., 
1994; Fu et al., 2004; Gupta & Lamont, 2004; Magaki, Yong, Khanlou, Tung, & Vinters, 
2014). Six studies reported that in the presence of dementia, it is less likely that a cancer 
diagnosis includes information on tumour size (cancer staging) (Baillargeon et al., 2011; 
Gupta & Lamont, 2004) and that cancer is diagnosed at a later stage of disease, compared to 
individuals without dementia (Odds Ratios; OR ranged from 0.97-2.31) (Bradley, Clement, & 
Lin, 2008; Gorin, Heck, Albert, & Hershman, 2005; Gupta & Lamont, 2004; Raji, Kuo, 
Freeman, & Goodwin, 2008; Tammemagi, Neslund-Dudas, Simoff, & Kvale, 2003).  
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[Table 3 insert here]  
2.3 Cancer treatment decisions 
Seven studies reported differences in cancer treatment decisions in samples of patients with 
cancer-dementia (see Table 3). Patients with a diagnosis of colon cancer and dementia were 
less likely to receive any treatment (OR 2.47), surgical (OR 0.43) or chemotherapy (OR 
range 0.21-3.23) treatment than those with cancer only (Baillargeon et al., 2011; Gupta & 
Lamont, 2004). Another study with a colorectal sample found patients with dementia were 
less likely to receive chemotherapy (12.5%) compared to other comorbidities such as 
congestive heart failure (44.8%) (Fleming et al., 2014). Similar findings were reported for 
breast cancer patients (Gorin et al., 2005; Kimmick et al., 2014). However, a dementia 
diagnosis had no impact on whether patients received cancer-directed surgery in a sample of 
nursing home residents with breast, prostate, colorectal or lung cancer (Bradley et al., 2008).  
When considering the hypothetical scenario of a relative with dementia receiving a breast 
cancer diagnosis, carers with a relative with more severe dementia symptoms expressed 
‘comfort care’ treatment as an option rather than treatment with curative intent (Smyth, 
2009).  
2.4 Health care professional’s views on cancer treatment in cancer-dementia 
Two studies investigated the influence of dementia on cancer treatment with health care 
professionals. A Dutch study found that in the previous 12 months 60% of clinicians recalled 
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one or more nursing home residents with suspected breast cancer and  a third (33%) chose not 
to refer for diagnostic testing or treatment (Hamaker et al., 2012). Of the 121 responses 
relating to reasons why patients were not referred, a diagnosis of end-stage dementia was the 
primary reason in over half of the cases (57%) and only 41% of decisions for non-referral 
were discussed with the patient. 
A small (n=5) qualitative study identified: the need for experienced staff and specialist care 
for dementia patients dying with cancer; the provision of support to families; involving 
families in patient care decision-making; HCPs experience frustration due to the 
communication difficulties often associated with dementia and recommend that a holistic 
approach should be taken (Bartlett & Clarke, 2012). 
Objective 3 
Studies relating to objective three are presented under the themes of management of cancer 
symptoms and cancer outcomes 
3.1 Management of cancer symptoms 
Seven studies explored the management of cancer symptoms in patients with cancer-
dementia (see final column, Table 3). Cross-sectional data indicated in two studies that as 
dementia severity increases, reported pain and administration of cancer pain medication 
decreases (Iritani, Tohgi, Miyata, & Ohi, 2011; Monroe, Carter, Feldt, Tolley, & Cowan, 
2012). Patients with cancer-dementia and higher scores on a cognitive ability scale used as a 
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proxy for dementia severity (higher scores indicated greater impairment) were less likely to 
be enrolled in hospice care for cancer than patients with lower cognitive impairment (OR 0.3) 
and hospice enrolment was associated with greater likelihood of receiving pain medication 
(OR 3.9) (Monroe, Carter, Feldt, Dietrich, & Cowan, 2013). In patients who died from a 
primary diagnosis of cancer and received hospice care in the six months prior to death, 
patients with cancer-dementia were more likely to use emergency health services, be 
admitted to hospital as an in-patient and no longer receive hospice services compared to 
patients with cancer alone (OR range 0.92-1.26) (Legler, Bradley, & Carlson, 2011). 
Additionally, data from geriatric drug prescription databases in the USA showed that hospice 
enrolled nursing home residents with cancer-dementia were more likely to receive daily pain 
medication (OR 1.25) but were still more likely to be hospitalised than those with cancer only 
(OR 1.09) (Miller et al., 2001; Miller et al., 2002). Lastly, co-morbid metastatic cancer and 
dementia was associated with a longer stay in hospital and greater health care costs compared 
to in-patients with dementia only; the same findings were not reported in patients with non-
metastatic cancer or lymphoma (Beydoun et al., 2015).  
3.2 Cancer outcomes 
Thirteen studies estimated the impact of a co-morbid diagnosis of dementia on survival 
and/or mortality risk in cancer patients (Baillargeon et al., 2011; Beydoun et al., 2015; 
Bradley et al., 2008; Chen et al., 2015; Daskivich et al., 2011; Erichsen et al., 2013; 
Louwman et al., 2005; Mohammadi et al., 2015; O’Rourke et al., 2008; Ording, Garne, et al., 
2013; Patnaik, Byers, DiGuiseppi, Denberg, & Dabelea, 2011; Raji et al., 2008; Tammemagi 
et al., 2003). Periods of follow-up ranged from up to five years to 17 years from year of 
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cancer diagnosis. All 13 studies reported an increased risk of death in patients with cancer-
dementia compared to cancer only (all-cause hazard ratios range from 1.45 – 3.74; see Table 
4). Five of these studies reported that those with cancer-dementia had a poorer survival rate 
than those with cancer and no comorbidity (Louwman et al., 2005; Mohammadi et al., 2015; 
Ording, Garne, et al., 2013; Patnaik et al., 2011; Tammemagi et al., 2003). 
[Table 4 insert here] 
Discussion 
This is a timely review given that the developed world comprises an ageing population with 
increased risk of developing both cancer and dementia. The primary aim of this review was to 
estimate cancer-dementia prevalence and describe the cancer-related journey of patients with 
cancer-dementia, their families and HCPs. In order to conduct a comprehensive review of the 
cancer-dementia literature, we used broad inclusion criteria and extracted data from a range 
of research methods that investigated a number of key themes including; cancer prevalence, 
cancer screening, diagnostic and treatment processes, cancer symptom management, and 
HCP views across these themes. We found no research that directly explored the views and 
experiences of patients. Furthermore, the review was limited by the sparse amount of studies 
evaluating the impact of cancer-dementia on cancer outcomes and poor low quality appraisal 
scores of included papers, with the majority of studies being retrospective and cross-
sectional. Only one of the three qualitative studies met any criteria for appraisal using the 
MMAT tool, although only received one star of a possible four (Torke et al., 2013).  
Page 12 of 55
URL: http:/mc.manuscriptcentral.com/camh





























































For Peer Review Only
13 
 
In this review, prevalence rates for cancer-dementia varied widely. This is likely due to 
heterogeneity in data collection methods and sample inclusion criteria. The SEER register 
used in seven studies only covered about a quarter of the US population so is unlikely to 
reflect true prevalence (Taylor, Ostbye, Langa, Weir, & Plassman, 2009). Half of the 
included studies also used small regional databases or individual hospitals and 24 studies 
reported prevalence of specific cancer types. The highest prevalence rates were reported by 
Miller and colleagues and are difficult to generalise given that the two samples were nursing 
home residents at end of life using hospice care (Miller et al., 2001; Miller et al., 2002). 
Additionally, the differences of reported dementia prevalence found between cancer and non-
cancer control group studies are likely also to be indicative of varied data collection methods. 
However, in the studies that collected multiple comorbidity data, the prevalence of cancer-
dementia was noticeably lower compared to other conditions such as diabetes, congestive 
heart failure and chronic obstructive pulmonary disease (Gross et al., 2006; Jorgensen et al., 
2012). No study provided sufficient data to comment on the presence of different types of 
dementia, the potential differences in cancer-related experiences and outcomes.  
Little published evidence relates to the impact of dementia on cancer screening beliefs and 
behaviours. This, in part, is due to the exclusion of older adults aged 74 and older from 
screening trials, at least for breast cancer (Schonberg et al., 2014; Walter & Schonberg, 
2014). The only study to investigate the impact of a dementia diagnosis on attending cancer 
screening found that patients were far less likely to attend colorectal screening if they had 
dementia, despite being a very small percentage of the total sample than for participants with 
no or any other comorbidity (Walter et al., 2009). The sample was aged 70 years or older so it 
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may reflect the general decrease in guideline recommended screening behaviour, which 
typically ends at age 75 years old in the USA, regardless of comorbidity.   
The review findings suggest that compared with other co-morbid disease groups, patients 
with dementia tend to be diagnosed with cancer at an unknown or later stage compared to 
patients with cancer only. This has likely implications for successful cancer treatment 
outcomes, potential to receive curative treatment and quality of life; as was found for 
comorbidities in general (Sarfati, Koczwara, & Jackson, 2016). Other findings have 
demonstrated that older age can significantly impact cancer treatment decisions over and 
above comorbidity levels (Lavelle et al., 2012). It may be that the patients with dementia 
included in this review had an advanced stage of disease or are older with associated health 
conditions such as frailty, which would impact on cancer treatment decisions. A recently 
developed framework for cancer-related end-of-life decision-making in the context of frailty 
could be adapted for use in patients with dementia (Amblàs-Novellas et al 2015). Schonberg 
and colleagues did attempt to describe the factors influencing clinician treatment decisions in 
females aged 80 or older with breast cancer, however it was not possible to extract data on 
treatment decisions in relation to co-morbid dementia (Schonberg, Silliman, McCarthy, & 
Marcantonio, 2012). Although eligible studies should have been identified with the search 
terms used for this review, no included study explored palliative or end-of-life decision-
making in patients with cancer-dementia and highlights an important and unmet research 
need in order to answer questions around treatment goals in this population. It could be that 
treatment goals are quality of life-based rather than for curative intent. This would suggest an 
even greater emphasis on the need for evidence-based guidelines to support cancer clinicians 
as well as patients with cancer-dementia and their caregivers.  
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Whilst studies in the review reported varied prevalence rates for cancer-dementia, 11 out of 
12 studies reported increased risk of death and poorer survival rates for this population 
compared to cancer only. Additionally, a co-morbid diagnosis of dementia inferred a greater 
risk of death than other comorbidities such as congestive heart failure including cancer 
discovery after death. It is well known that multi-morbidity in older people negatively 
impacts on quality of life, but it is not yet clear why there appears to be a specific higher 
mortality risk in those with cancer-dementia (Marengoni et al., 2011). One explanation could 
be the greater risk of death associated with frailty in older people; however none of the 
included studies assessed the specific impact of this on cancer outcomes (Handforth et al, 
2015). 
The number and quality of papers reporting management of cancer symptoms in patients with 
cancer-dementia was low as demonstrated by the quality appraisal tool used to score each 
study. Our review demonstrates that dementia-related impairments are likely to be related to 
suboptimal cancer-related pain assessment and management practices although further 
research is need to confirm these results (Monroe et al., 2012; Monroe et al., 2013). It is well 
documented that people with dementia, without a cancer diagnosis, find it difficult to verbally 
communicate their experiences of pain and that tools used to assess pain need to be 
appropriate and sensitive to the needs of people with dementia (Dowding et al. 2016; 
Lichtner et al., 2016). A single study reported increased use of emergency services and 
inpatient hospitalisation in patients with cancer-dementia; another reported greater healthcare 
costs for metastatic cancer although both were American studies with limited generalizability 
(Beydoun et al., 2015; Legler et al., 2011). As yet, the economic impact of cancer-dementia, 
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although likely to be substantial in the absence of adequate clinical and support services, 
remains unknown.  
This review included limited research that explored health care professionals’ views and 
experiences in relation to cancer-dementia care at any stage of the cancer screening, diagnosis 
and treatment pathways. It is important to establish cancer treatment goals despite age or 
comorbidity as set out in recommendations for palliative support of patients with dementia 
(Naik, Martin, Moye, & Karel, 2016; van der Steen et al., 2013). Given that we were unable 
to locate any high quality evidence of HCPs cancer treatment decision-making experiences 
for patients with cancer-dementia, future research should focus on exploring this given that 
we have reported lower likelihood of receiving cancer treatment and higher mortality risk in 
patients with co-morbid dementia.  
Clinical and policy implications 
It is clear that the findings from this review indicate that a co-morbid diagnosis of cancer and 
dementia has particular implications for healthcare service use, care management and 
delivery, which should be reflected in government policy and health guideline updates. At 
present, although quality standards published by the National Institute for Clinical Excellence 
(NICE, 2010, QS1) reflect that clinicians supporting patients with dementia should be 
adequately trained to provide dementia care, there is no mention of education regarding 
complex treatment decision-making discussions. However, there is a growing 
acknowledgement that there are specific priorities for the older population nationally and 
internationally that need to be addressed. For example, in the UK, implementation guidance 
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on the second Prime Minister’s challenge on dementia (Department of Health, 2016) 
advocates dementia-related research including comorbidity in older adults. Considerations 
also need to be made for the development of appropriate decision-making frameworks for 
this vulnerable population given the complexity clinicians, patients and their families’ face, 
which has been alluded to in the findings from this review. Future work may involve 
conducting a systematic search of the grey literature to clarify this. 
Conclusion 
There is substantial variation in the reported cancer-dementia prevalence rate yet cancer-
dementia appears to present as a unique challenge for the patient, carer and clinicians. 
Additional work is required to investigate the impact of different levels of dementia severity 
on the cancer pathway from prevention, diagnosis to end of life. Further investigations are 
warranted to understand and optimise the cancer care pathways for these at-risk individuals. 
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Table 1 Studies included in the review, organised by objective(s) (n = 47) 
Authors & 
country of study 
Study design Study aim/objective(s) Sample 
size (N) 
Participants & setting Relevancy to review 
objective(s) 
Study Appraisal score 
study type; * (%quality 
criteria met) 
 




Investigated the role of 





Cancer Registry of southern 
Sweden (2005-2007) patients 
affected by dementia 90 days 
prior to diagnosis of cancer 
(invasive tumours excluded) 
Prevalence  *** 
  




To evaluate the determinants 
and the effect of treatment on 
prognosis among women aged 
over 80 years who are 
diagnosed with breast cancer. 
407 Breast Geneva Cancer Registry (1989-
1999) female patients aged 80 or 
older  




Moran, & Chen, 
2010) 
Cohort study To evaluate the risk of death 
from AD in men undergoing 
therapy for prostate cancer 
with or without a LHRH 
agonist. 
6647 Prostate Chicago Prostate Cancer Centre 
– patients undergoing 
brachytherapy treatment only 
(1997-2007) 
Prevalence *** 
(Derogatis et al., 
1983) 
USA 
Cross-sectional To estimate the prevalence of 
psychiatric disorder among 




Patients over 19 years at 3 
medical centres newly admitted 
for active cancer treatment  
Prevalence ** 




To determine the degree to 
which life expectancy after 
diagnosis of early stage 
cancer varies according to age 
or co-existing chronic illness   
35,755  SEER Register 1993-1999 
patients over 67 years with 
colorectal cancer diagnosis  
Prevalence   ** 
USA  






To estimate treatment effect 
of Medicare hospice benefit 
on end of life government 
expenditures among nursing 
home residents 
5774 All nursing home residents in 
Florida who died Jul-Dec 1999 
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To describe the prevalence of 
comorbidity in newly 
diagnosed elderly cancer 
cases compared with 
background population and its 
influence on overall and 
cancer-specific mortality 
6,325 Multiple Danish Cancer Registry from a 
Danish province (1996-2006) 
Prevalence  **** 
Denmark   
   
   
(Koroukian et al., 
2006) 
Cross-sectional To assess prevalence of 
comorbidity, disability and 
geriatric syndromes or a 
combination thereof in elders 
with cancer receiving home 
health care 
952 Breast Ohio Cancer Incidence 
Surveillance system (Aug 1999- 
Nov 2001) patients 65 years or 
older diagnosed with cancer  
Prevalence * 
USA   
 324 Prostate  








To compare analgesic 
management of daily pain for 
dying nursing home residents 
enrolled and not enrolled in 
Medicare hospice 
2,644 enrolled Systematic assessment of 




USA    
 7,929 not 
enrolled 
 
(Minagawa et al., 
1996) 
Cross-sectional To clarify the nature and 
prevalence of psychiatric 
disorders in terminally ill 
cancer patients 
93 Cancer patients newly admitted 
to a hospital palliative care unit 
(1994-1995)  
Prevalence ** 
Japan   
(Nugyen-Nielson 




To examine the impact of 
comorbidity on overall 
prostate cancer survival in the 
12-year study period 
7654 Central Denmark Region: 
Danish National Registry of 
Patients with first time diagnosis 
of cancer in 2000-2011 
Prevalence  *** 
 median age 72 years   
  46/7654 = 0.6% can-dem 
prevalence (reducing over time 
in the study period) 
 
    
  Further analyses conducted with 
CCI only 
 
Page 26 of 55
URL: http:/mc.manuscriptcentral.com/camh





























































For Peer Review Only
27 
 




To study temporal changes in 
mortality in a cohort of breast 
cancer patients diagnosed in 
2000-2011 by extent of co-
morbid diseases 
9,239 Central Denmark region, Danish 
National Registry of Patients 
(2000-2011, females, first time 








To compare mortality rates 
for prostate cancer patients 
with that of men from the 
general population and 
examined whether prostate 
cancer and specific comorbid 
conditions interact to increase 
mortality more than expected 
by each factor acting alone 
45,326 Danish Cancer Registry patients 








To determine the impact of 
co-existing psychiatric illness 
on time to diagnosis, disease 
stage and survival in patients 
with cancer  
160 Veteran hospital patients 










To identify factors that 
influence the breast cancer 
treatment decisions of women 
aged 80 and older 
65 Female, aged 80 or older at 3 
health centres (1994-2004 and 








To examine (i) the prevalence 
of comorbidity from 1995 to 
2004 and (ii) the impact of 
comorbidity on ovarian 
cancer survival and mortality 
during the study period. 




(Zeber et al., 
2008) 
Cross-sectional To examine the prevalence, 
medical comorbidities and 
treatment modalities of four 
commonly diagnosed cancers 
(Lung, colorectal, prostate, 
197,797 Veterans Health Administration 
national database (2004-2005) 
patients aged 70 or older 
Prevalence  ** 
USA  
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head and neck) among 
veterans affairs patients aged 








To explore the nature of 
breast cancer screening and 
treatment decisions in older 
women with dementia 
23 Caregivers of women with 
dementia (15 spouse, 2 sons, 4 
daughters, 1 niece, 1 friend)  
Cancer screening - 
     
  of 6 severe, 9 mild, 8 moderate 
dementia 
Cancer treatment decisions  




To describe perspectives of 
family caregivers toward 
cancer screening tests for 
their relatives with dementia 
32 Caregivers attending dementia 
support group meetings (mostly 
daughter or spouse; 5 other)  
Cancer screening * 
   
   




To determine whether 
colorectal cancer screening is 
targeted to healthy older 
patients and is avoided in 
older patients with severe 
comorbidity who have a life 
expectancy of less than 5 
years 
27,068 National veteran systems (2001-
2007) patients 70 years or older 
with at least 1 outpatient visit 
during 2000 (96% males age 77 
median) 
Cancer screening ** 
USA  
  




To compare autopsy 
incidence of cancer between 
Alzheimer’s disease cases and 
a non-Alzheimer’s control 
group 
646 University hospital 
histopathology reports (1983-
1988) 
Cancer diagnosis  ** 
(Fu et al., 2004) Autopsy chart 
review 
To examine general autopsy 
findings in patients with a 
dementia syndrome and to 
establish patterns of central 
nervous system comorbidity 
in these patients 
52 Patients who had general 
autopsy and clinical diagnosis of 
dementia (1995-2000) at a large 
academic medical centre 
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To examine systemic and 
central nervous system 
comorbidities of individuals 
with dementia evaluated 





Completed autopsy reports and 
clinical information of deceased 
patients from a tertiary medical 
centre 
Cancer diagnosis ** 
   




Examined the clinical, socio-
demographic and provider 
determinants of variation in 
concordance with widely 
accepted treatment guidelines 
for colorectal cancer patients 
2,932 stage 1-3 
colon cancer 
diagnosis 
New colorectal diagnoses as per 
Medicare claims assessed (2005-
2009 in 4 States  
Cancer treatment * 
 184 rectal 
cancer 
diagnosis 
Patients we less than 80 years 
and scheduled for chemotherapy 
or radiotherapy 
   
     
(Kimmick et al., 
2014) USA 
Cross-sectional   To explore the relationship 
between level and type of 
comorbidity and guideline 
concordant care for early-
stage breast cancer  
6,439 National Program of  Cancer treatment decisions *** 
 Cancer Registry females with 
breast cancer from  
 
 (2004)   






How do HCPs assess the 
needs of an older person 
dying from cancer with a 
coincidental dementia? 
5  HCP within a single acute 
hospital 








To determine the extent of 
non-referral of patients 
suspected of breast cancer by 
elderly care physicians and 
the motivations behind this 
choice  
419 Elderly care physicians across 
the Netherlands 









To use medical records to 
assess advanced cancer pain 
in older adults with dementia 
at the end of life 
48 Nursing home residents in final 
3m of life 









To examine the association 
between hospice enrolment, 
55 Deceased nursing home residents 
with dementia who had 
Management of cancer 
symptoms 
* 
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dementia severity and pain 
among nursing home 
advanced cancer 




Danieli et al., 
2006)  
Retrospective 
chart review  
To study the effect of age, 
comorbidity, tumor features 
and treatment appropriate to 
overall survival and breast 
992 Institutional Tumor Registry 
(1971-2001) females aged 70 or 
older  
Prevalence ** 
USA    
 Cancer diagnosis  
   




To report use of breast cancer 
treatment by patients with 
Alzheimer's Disease 
50,460  SEER Register (1992-1999) 
females over 64 years stage I-III 
breast cancer  
Prevalence *** 
USA   
 Cancer diagnosis  
   
 Cancer treatment decisions  
(Legler et al., 
2011) 
Cross-sectional  To estimate the comorbidity 
burden of hospice users with a 
primary diagnosis of cancer 
and burden on admissions, 
hospice disenrollment and 
death 
27166 SEER Register, any patient in 
2002 with cancer who died and 
received hospice care in 6m prior 
to death 
Prevalence  * 
USA   
 Management of cancer 
symptoms 
 




To evaluate whether Medicare 
hospice care provided in 
nursing homes is associated 
with lower hospitalisation 
rates 
36,702 Systematic assessment of 
geriatric drug use via 
epidemiology database  
Prevalence ** 
 1992-1996 (died before January 
1998)  
  
  Management of cancer 
symptoms 
 
    




To evaluate how dementia 
modified the cancer discovery 
process, pain reports and 
medication use at a large 
134 Patients from surgical ward for 
cancer treatment (1993-2004; 
leukemia and skin cancer 
excluded)   
Prevalence - 
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 psychiatric hospital     
    Cancer diagnosis   
    







To examine the independent 
and aggregate effects of a pre-
existing diagnosis of any 
major mental disorder on 
cancer stage at diagnosis, 
treatment and survival in 
adults with colon cancer  
80,670 Medicare database Prevalence *** 
USA (Jan 1993-Dec 2005)   
 patients aged over 67 years colon 
cancer diagnosis 
Cancer diagnosis  
    
  Cancer treatment decisions  
    
  Cancer outcomes   




To assess over-time trends in 
Alzheimer’s Disease (AD) 
prevalence among a US 
inpatient sample; to compare 
comorbidities between AD 
and non-AD admissions; to 
compare outcomes (mortality 
rate, length of stay and total 
charges) and trends of 
comorbidity 
14,126 445 
(weighted)   
Nationwide inpatient sample 
(2002-2012) aged 60 or older 
and discharged (with notes) 
Prevalence  * 
USA   
 Management of cancer 
symptoms 
 
   
 Cancer outcomes   
   
   




To understand the patterns of 
care provided to nursing 
home cancer patients 
1,907 Medicaid/Medicare data merged 
with Michigan Tumor Registry 
(1997-2000) nursing home 
residents aged 66 or older  
Prevalence  *** 
USA   
 Cancer diagnosis  
   
 Cancer treatment decisions  
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 Management of cancer 
symptoms 
 
   
 Cancer outcomes  
(Chen et al., 
2015) 
Retrospective 
cohort study  
To determine the prevalence 
of medical conditions in 
patients with cancer and their 
impact on outcome 
37,411 Longitudinal Health Insurance 
Database (Jan 2000-Jan 2008) 
adult patients over 20 years who 
visited health care facilities 
(insured patients) 
Prevalence  * 
Taiwan   
 Cancer outcomes  





cohort study  
To examine the impact of 
severe co-morbid disease 
history and survival in 
patients with myeloid 
leukemia or myeloma in 
Sweden 
8,134 Swedish Cancer Registry (2002-
2009) myeloid leukemia or 










To determine the long-term 
risks of non-prostate cancer 
mortality associated with 
specific comorbidities 
1,598 Patients with prostate cancer at 
two veterans hospitals (1997-
2004) 
Prevalence ** 
USA   
 Cancer outcomes  
   




To study the interaction 
between comorbidity and 
colorectal cancer, and 
subsequent risk of death. 
56,963 Danish Cancer Registry 
colorectal cancer patients (1995-
2010) 
Prevalence *** 
Denmark    
 Cancer outcomes  





To describe the prevalence of 
serious comorbidity and 
impact of comorbidity on 
treatment and prognosis in 
breast cancer  
8,966 Breast Cancer Registry (1995-2001) all 
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To determine the prevalence 
of dementia in older patients 
diagnosed with colon cancer 
and the influence of co-
morbid dementia on 
presentation, diagnosis and 
treatment 
17,507 SEER Register (1992-1999) 
patients over 67 years with colon 
cancer stage I-III (dementia 
diagnosis two years preceding 








    
(Ording, Cronin-




To estimate the different 
between overall mortality rate 
and the expected mortality 
rate, effect of breast cancer on 
mortality rate and 
comorbidity 
47904  
n = 237938 
matched 
control 
Breast cancer patients aged 45-
85 diagnosed during 1994-2008 
Prevalence *** 
  Civil Registration System    
   Cancer outcomes  
     
   0.5% n231 dementia in breast 
cancer; 0.4% n1028 non-cancer 
matched group 
 
   Mortality rate risk during first 
year since diagnosis: 5.0 CI 3.6-
6.8 (no p value) 
 
   stage distribution skewed 
towards later stage diagnosis for 
breast and dementia patients 
compared with breast cancer 
patients without dementia' 
 




To measure associations 
between specific 
comorbidities and overall 
survival/all-cause mortality in 
older women with breast 
cancer 
64,034 SEER Register (1992-2000) 
females over 66 years  
Prevalence *** 
USA   
 Cancer outcomes  
(Raji et al., 2008) Retrospective 
cohort  
To examine the effect of a 
pre-existing diagnosis of 
dementia on deaths from 
cancer (colon, breast, 
31,935 breast SEER Register (1994-1999) 
patients over 68 years  
Prevalence *** 
USA 47, 235 
prostate 
  
 26,891 colon Cancer diagnosis  
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 prostate)    





To evaluate the effect of 
comorbidities individually 
and collectively on the 
survival of lung cancer 
patients and what extent 
existent effects are mediated 
through differences in receipt 
of cancer treatments  
1,115 Jospehine Ford Cancer Tumor 
Registry (Jan 1995-Dec 1998, 
follow up 2000)  
Prevalence * 
USA   
 Cancer diagnosis  
   
 Cancer outcomes  
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Table 2 Prevalence of cancer-dementia from included studies, organised by cancer type 












Prevalence of co-morbid 
dementia %  
(n= sample size) 
(Bouchardy 
et al., 2003)  




80 or older 12.9 (n=42/326)* 
*20% total sample had no 
comorbidity data 






64 or older 3.8 (n=1,935/54,460) 
(Louwman et 
al., 2005) 

























Non cancer controls 0.4 
(n=1,028/237,938) 
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66 or older 1.4 (n =887/64,034) 
(Schonberg 










80 or older 12.3 (n=8/65) 
(Siegelmann-





tumour registry of 
a medical centre 
1971-
2001 
70 or older 4 (n=40/992) 
(Tammemagi 

















et al., 2011)  
USA Colon SEER register 1993-
2005 
67 or older 9 (n=7,267/80,670) 
(Erichsen et 
al., 2013) 









Non cancer controls 
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 0.8 (n=2,297/271,67) 
(Gross et al., 
2006)  
USA Colorectal SEER register 1993-
1999 




USA Colon SEER register 1992-
1999 
67 or older 6.8 (n= 1,184/17,507) 
(O’Rourke et 
al., 2008) 












Denmark Ovarian University hospital 
database serving 







0.2 (n=4/1,995)  
(Mohammadi 
et al., 2015) 






















USA Prostate Chicago prostate 
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USA Prostate California Cancer 
Registry, Two 
veterans hospitals 
































0.6 (n = 294/45,326) 
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(Raji et al., 
2008) 




68 or older 7 (n=7,453/106,061) 
Breast: 7.4 (n=2,369/31,935) 
Colon: 10 (n=2,691/26,891) 
Prostate: 5.1 (n=2,393/47,235) 





























60 or older Lymphoma 
 *weighted sample *1.1 (n=15,5391/14,126,445) 
  Metastatic cancer 
  *3 
(n=423,793/14,126,445) 
   Non-metastatic cancer 
  *3 (n=423,793/14,126,445) 
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66 or older Non cancer controls 1.9 
(n=2,732/147,324) 










20 or older 
(mean/median 
not reported) 
2.2 ( n = 831/37,411) 
(Derogatis, 
Morrow, 






centres (2 in NY, 1 


















70 or older 0.85 (n=54/6,325) 
Non cancer controls 1.16 
(n=294/21,868) 
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Palliative care unit 
















USA Not specified Nursing home 







65 or older 6.15 (n=355/5,774) 
(Miller et al., 
2001) 
USA Not specified Systematic 
Assessment of 
Geriatric Drug Use 
via Epidemiology 










(mean age 84) 
Hospice 32 (n=2,836/9,202) 
Non cancer controls 16 
(n=1,478/9,202) 
(Miller et al., 
2002) 
USA Not specified Systematic 
Assessment of 
Geriatric Drug Use 
via Epidemiology 












Hospice 43.2 (n=306/709) 
Non cancer controls 28.5 
(n=202/709) 
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Table 3 differences in cancer staging and treatment decisions in people with and without com-morbid dementia 
Study Cancer 
type 
















Impact of dementia on 
management of cancer 
symptoms 
OR (confidence intervals) 
unless otherwise stated 
    Dementia Cancer 
only 
Stage Dementia Cancer 
only 
   
(Baillargeon 






















No treatment(all stages) 
Adj RR 2.47 (2.08-
2.93) 





treatment (stage III) 
Adj RR 3.23 (2.66-
3.91) 
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 - - - - - - - Length of hospital stay 
Lymphoma 
-0.11 days p=0.66 
Metastatic cancer 
+0.78 days p<.001 
Non-metastatic cancer 
+0.04 days p=0.81 
 










Colorectal 4 State 
cancer 
registries 
 - - - - - - Stage III colon 
1/8 with dementia 
received chemotherapy 
 
Stage I-III colorectal 
- 
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 - - - - - 8% (n = 4/52) had 
undiagnosed 
malignancies 






















cancer at autopsy 
2.31 (1.79-3.00) 
Un-staged cancer  
2.12 (1.77-2.55) 
Less invasive 



































No treatment decision 
recorded 
3.7% dementia 
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- Reporting pain (nurse records) 
22% with dementia 
76% without dementia 
 
Received pain medication at 
cancer stage IV 
13% with dementia 

















 - - - - - - - Emergency Room visit 
9.3% v 6.7%  
1.26 (1.12-1.41) 
Inpatient admission 
7.4% v 5.5% 
1.21 (1.05-1.40) 
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Intensive Care Unit 
1.1% v 0.9% 
1.13 (0.81-1.59) 
Disenrollment from hospice 
12.3% v 9.6%  
1.18 (1.05-1.32) 
Hospital death 








 - - - - - 7% (6/86) had 
undiagnosed 
malignancies 
during autopsy [no 
control group] 
- - 






 - - - - - - - Hospice enrolment and 
hospitalization 












 - - - - - - - Hospice enrolment and 
treatment of daily pain 
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 - - - - - - - Dementia severity (cognitive 
performance scale) and opioid 
medication administration  
-0.44 p = 0.001 (spearman’s 
rank correlation) 
Dementia severity and pain 
behaviour (discomfort 
behaviour scale)  









 - - - - - - - Hospice enrolment and pain 
medication administration 
3.9 (1.1-14.0) = = 0.037  
Severe stage of dementia and 
pain medication administration 
(controlling for hospice 
enrolment) 
0.3 (0.1-0.8) p=0.030 




















- - - 












- - - 












- - - 
(Siegelman-
Danieli et al., 
Breast Academic 
medical 






- - - 
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 - - - - - Later or un-staged 
diagnosis 
2.01 (1.18-3.43) 
0.3% (stage I-II) 
2.6% (stage III-IV 
or un-staged) 
- - 
* All values in this column are significantly different p<0.001; ᴬ All bold values p<0.001; 
B
 All bold and italicised values p<0.01; 
$
comparison group had psychiatric disorders; OR odds ratio 
Page 48 of 55
URL: http:/mc.manuscriptcentral.com/camh





























































For Peer Review Only
49 
 
Table 4 Mortality risk and cancer-dementia 
Study Cancer type Participant setting Date range 
included in 
analyses  
Survival  Risk of Mortality in cancer-dementia compared to 
cancer alone or non-cancer controls 









Sample (35 US states) 
2002-2012 
Analyses presented 
here were on 
patients discharged 
in 2012 
- Lymphoma MR on discharge 1.05 (0.68-1.63) p=0.83 
Metastatic cancer MR on discharge 1.72 (1.29-2.28) 
p< 0.001 
Non-metastatic cancer MR on discharge 1.08 (0.85-
1.38) p=0.51 








Tumor Registry  
1996-2000 
Follow up until 
death or Dec 2003  
48% total sample had died within 3 months of 
cancer diagnosis 
Risk of death within 3 months of diagnosis  
OR 1.33 (1.04-1.70) p = 0.026 
Relative risk of death within 3 months of diagnosis  




Colon SEER database 1993-2005 Analyses restricted to patients who survived at 
least 6 months 
No other information available  
All-cause HR 1.45 (1.40-1.50) 
Cancer-specific HR 1.41 (1.34-1.48) 
(Greater than risk from any other psychiatric illness)  








patients who visited 
2000-2008 
Follow-up of at 
Accounted for 39.3% of deaths [highest of all 
co-morbid conditions and compared with 11.5% 
if no comorbidity] 
HR 5.02 (2.77-9.09) p <0.001 
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health care facility for 
cancer diagnosis 
least 1 year 
(Daskivich et 
al., 2011) 
Prostate Two veteran hospitals 1997-2004 - HR 2.9 (1.9-4.3) p<0.0001 
(Erichsen et al., 
2013) 
Prostate Danish Cancer 
Registry 
1995-2010 0-1 years MR 1010 deaths per 1000 person-
years 2-5 years MR 318 deaths per 1000 person 
years 









Followed up until 
Jan 2004 
At 70 years (crude survival) 
1 year: 83% v 93% p<0.01 
5 year: 27% v 68% p<0.01 (lower than even 
having 2 or more concomitant diseases – 35%) 










or Dec 2012 
Per 10 person years, dementia had higher rate of 
death than any other comorbidity whether 
cancer specific (all 3 types) or all-cause death  
AML 
All-cause MRR 1.51 (0.97-2.33) 
AML specific MRR 1.75 (1.11-2.76) 
CML 
All-cause MRR 2.59 (1.28-5.26) 
CML specific MRR 1.19 (0.35-4.02) 
Myeloma 
All-cause MRR 1.61 (1.15-2.24) 
Myeloma specific MRR 1.87 (1.25-2.79) 
(Ording, 
Cronin-Fenton, 









Interaction between breast cancer and dementia: 
Year 0-1: 148 deaths due to cancer and 
dementia (per 1000 person-years) 
In first year of cancer diagnosis 
MRR 5.0 (3.6-6.8)  
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or Dec 2011  




Oesophagus  Veteran hospital 1989-2003 - HR 2.98 (1.35-6.60) 
(Other psychiatric illnesses did not predict shorter 
survival time) 
(Patnaik et al., 
2011) 
 
Breast SEER database 1992-2000 
Follow up until 
death or Dec 2005 
5-year survival rate 
18.9% n= 168 (CI 16.4-21.6) compared to 
74.9% if no comorbidities [not statistically 
analysed] 
All-cause HR 1.96 (1.82-2.10) p <0.001 
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SEER database 1994-1999 
Follow up until 
death or Dec 2001 
  
Breast                          
Year 1 mortality       Year 1 mortality  
Cancer specific:        Non cancer  
3.8%(2.7-4.7)            6%(4.8-7.3) 
Year 5 mortality        Year 5 mortality 
Cancer specific:         Non cancer 
4.8% (1.4-8.4)            15.6% (11.2-20.2) 
Colon                          
Year 1 mortality       Year 1 mortality  
Cancer specific:        Non cancer  
7.9%(5.8-10.1)           7.7%(6.0-9.5) 
Year 5 mortality        Year 5 mortality 
Cancer specific:         Non cancer 
3.5% (-0.9-8.1)           12.8%(8.4-17.4) 
Prostate                          
Year 1 mortality       Year 1 mortality  
Cancer specific:        Non cancer  
0.8%(0.3-1.3)           1.7%(1.0-2.5) 
Year 5 mortality        Year 5 mortality 
Cancer specific:         Non cancer 
2.8% (0.4-5.5)            12.7%(8.4-17.2) 
Breast 
Cancer specific HR 1.52 (1.37-1.68) 
Other causes HR 2.17 (2.03-2.32) 
Overall death HR 1.96 (1.85-2.07) 
Colon 
Cancer specific HR 1.44 (1.35-1.55) 
Other causes HR 1.80 (1.68-1.92) 
Overall death HR 1.56-1.72) 
Prostate 
Cancer specific HR 1.63 (1.47-1.81) 
Other causes HR 1.93 (1.81-2.06) 
Overall death HR 1.93 (1.83-2.04) 
(All analyses presented p<0.001) 





Jospehine Ford Cancer 
Tumor Registry 
1995-1998 Median survival 0.12 years compared to  overall 
0.86 years (p<0.001) [over the five year follow-
HR 3.42 (2.24-5.23) p < 0.0001 [Univariate  
comorbidity] 
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 Follow-up until 
Jan 2000 
up] 
HR 1.10 (0.63-1.93 p=0.74 [adjusted for baseline co-
variates, cancer treatment and all other comorbidities] 
Boostrap HR 3.74 (2.17-5.42) [adjusted for baseline 
co-variates] 
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Figure 1 Flow diagram of studies included in this review 
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Figure 1 Flow diagram of studies included in this review 
 
Records identified through database searching 
(n = 1364; 81 Psychinfo, 560 CINAHL, 
390 EMBASE, 62 BNI, 271 Medline) 
Additional records identified through other sources  
(n = 21) 
Records after duplicates removed  
(n = 1009) 
Records excluded from 
title/abstract  
(n = 892) 
Full-text articles assessed for 
eligibility  
(n = 138) 
Full-text articles excluded, with 
reasons:  
n = 63 not co-morbid 
n=4 excluded history of 
dementia 
n = 14 couldn’t exact sufficient 
data  
n=6 not confirmed dementia 
diagnosis 
n = 3 sample had cancer only at 
baseline 
Studies included with 
quantitative design  
(n =44) 
Studies included with qualitative 
design  
(n =3) 
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